1. Introduction {#sec1}
===============

Behçet\'s disease (BD) is a multisystem disease characterized by recurrent oral and genital ulcers and relapsing uveitis with mucocutaneous, articular, neurological, urogenital, vascular, intestinal, and pulmonary manifestations. Most patients with BD experience recurrent aphthous stomatitis (RAS), which is often the initial feature of the disease \[[@B1]\]. The prevalence of RAS has been reported to vary between 1% and 66% among adults \[[@B2], [@B3]\]. BD patients may suffer more RAS events in daily life than do individuals in the general population, although the descriptive data on RAS are insufficient.

Previous studies have detailed the impact of BD, including its symptoms and disease activity, on quality of life (QOL) \[[@B4]--[@B13]\]. Blackford et al. \[[@B4]\] found that oral and genital ulcerations in particular affected patients\' personal relationships. BD patients with ocular involvement have been reported to be susceptible to anxiety and depression \[[@B5]\]. Arthritis had a significant effect on both the pain level and QOL of patients with BD, leading to an increased risk of mental distress, including anxiety or depression \[[@B8]\].

Oral health status is closely associated with QOL \[[@B14]\]. Tabolli et al. \[[@B15]\] showed that oral mucosal conditions could have a radical effect on oral health-related QOL (OHQOL). Mumcu et al. \[[@B9]\] reported that BD patients with active oral ulcers reported relatively poor OHQOL compared with ulcer-free patients. OHQOL was worse in BD patients than RAS patients, whereas BD patients exhibited a prolonged healing time for oral ulcers, and RAS patients showed an increased frequency of oral ulcers \[[@B9]\].

The extant data are insufficient for clarifying the effects of oral aphthous ulcers (OAUs) on the OHQOL of patients with BD. To our knowledge, no study has analyzed a large dataset including a control group from the general population. Therefore, the aim of this study was to investigate the annual prevalence of OAUs and their association with OHQOL in BD patients and to compare them with those in the general Japanese population.

2. Materials and Methods {#sec2}
========================

2.1. Study Subjects {#sec2.1}
-------------------

Two groups of subjects participated in this study, patients with BD (BD group) and individuals representative of the general population (control group). For the BD group, a cross-sectional study was performed of all members of the Japanese Association for Patients with Behçet\'s Disease between October 2004 and January 2005. The control group was selected via stratified, multistaged random sampling from 200 locations in Japan. Stratification was performed according to area and municipality based on national census figures. To obtain first-stage sampling units, municipalities were sampled for each stratum. For second-stage sampling, survey units were randomly sampled for each stratum. To obtain third-stage sampling units, individuals from the Basic Resident Registry who were eligible for participation in the survey and resided within the survey areas were systematically sampled at regular intervals. The cross-sectional study was performed in February 2006.

Questionnaires were administered to 2,400 potential control subjects and 1,358 BD patients aged 15--79 years and 17--91 years, respectively. The Ethics Board of iHope International approved this study protocol in October 2004, and the Ethics Board of the Nagoya University School of Medicine approved the study protocol in December 2005.

2.2. Instruments {#sec2.2}
----------------

The questionnaire packet included items regarding oral health status, current number of teeth, and the Japanese version of the General Oral Health Assessment Index (GOHAI). The GOHAI contains 12 questions, each of which is scored between 1 and 5; total scores range from 12 to 60---a higher total score indicates a better OHQOL.

The GOHAI, an instrument designed to assess OHQOL, was originally developed in the United States for use among elderly individuals \[[@B16]\]. The Japanese version of the GOHAI questionnaire has been adapted for and validated in the Japanese population \[[@B17]\]. The national norms for Japanese are available online \[[@B18]\]. This index defines health-related QOL as a person\'s assessment of how the following affects his or her well being: functional factors, psychological factors, social factors, and the experience of pain or discomfort. When the assessment is focused on orofacial concerns, OHQOL is assessed \[[@B19]\].

Patients in the BD group self-reported disease information. They were evaluated for disease severity according to the criteria proposed by the Behçet\'s Disease Research Committee of Japan in 2003 \[[@B20]\].

2.3. Data Analysis {#sec2.3}
------------------

Differences in GOHAI scores and in the frequency and duration of OAUs were analyzed using *t*-tests. For purposes of data analysis, GOHAI scores were treated as dichotomous categorical outcome variables. Group (i.e., control with or without OAUs, BD with or without OAUs) was included as an independent variable. Covariates included age and sex. Age-adjusted and multivariate-adjusted logistic regression models were used to assess the association between BD, experiencing OAUs at least twice per year ("with OAUs" was defined as ≥2 outbreaks during the past year), and the risk of scoring below the national norms on the GOHAI (GOHAI score = 53.1). Responses were analyzed after excluding subjects with missing data related to their OAU 1-year period prevalence, GOHAI scores, or BD diagnosis.

Mean values are reported with standard deviations (SDs). Odds ratios are reported with 95% confidence intervals (95% CIs). All *P*-values were two sided, and *P* \< 0.05 was considered to indicate statistical significance. Analyses were performed using the IBM SPSS Statistics software (version 20 for Windows; IBM Corporation, New York, NY, USA).

3. Results {#sec3}
==========

3.1. Response Rates and Compositions of Final Groups {#sec3.1}
----------------------------------------------------

Responses were obtained from 1,170/2,400 potential control subjects (response rate = 49%) and 883/1358 patients with BD (response rate = 65%). Analyses were limited to data from subjects aged 20--79 years because most respondents (1,122/1,170 controls, 867/883 BD patients) were in this age range. Both sexes were well represented in both groups. The final data analysis was conducted after 192 patients and 25 controls were excluded due to incomplete data. The mean age of the final control group (50.8 ± 15.7 years) differed significantly from that of the final BD group (55.5 ± 12.5 years; *P* \< 0.001). The demographic characteristics of the BD group and those of participants in the National Survey of BD patients in 2002 \[[@B21]\] were similar. The mean ages of males were 50.2 and 47.8 years and those of females were 51.3 and 51.3 years in the BD group and the National Survey, respectively. The respective male: female ratios were 1.07 and 0.93.

The mean disease duration for BD patients was 22 ± 12 years (range, 1--50 years). The most common drug treatments used by BD patients were colchicines and steroids. Detailed data on the demographic characteristics of both groups and the disease severity of and drug treatments used by BD patients are presented in [Table 1](#tab1){ref-type="table"}.

3.2. Characteristics of the 1-Year Period Prevalence of OAUs {#sec3.2}
------------------------------------------------------------

We found that 83.9% of BD patients and 31.0% of controls, regardless of age, had OAUs during the prior year. The mean number of OAUs per year was 12.7 (SD = 31.5) in BD patients and 1.1 (SD = 2.4) in the control group. BD patients experienced OAUs significantly more frequently than did controls ([Table 2](#tab2){ref-type="table"}).

Among patients with BD, more males than females in all age groups, with the exception of 40--59 years, reported having had OAUs. We found a significant difference between males and females in the 1-year period prevalence of OAUs only among those aged 30--39 years (*P* = 0.042). The mean number of persons having OAUs decreased significantly with age among males (*P* = 0.007). In the control group, more females than males in all age groups, except those aged 20--29 and 60--69 years, reported having had OAUs. The mean number of persons having OAUs decreased significantly with age among both males and females (*P* \< 0.001). Detailed data on the frequency of OAUs in each group according to sex and age are presented in [Table 2](#tab2){ref-type="table"}.

The mean duration of OAUs was 55.3 ± 76.4 days in the BD group and 4.7 ± 12.1 days in the control group. The duration of OAUs suffered by BD patients was substantially longer than was that experienced by members of the control group, irrespective of sex. The trends in duration for each age category were congruent with the frequency data. Detailed data on the frequency of OAUs in each group by sex and age are provided in [Table 2](#tab2){ref-type="table"}.

Among patients with BD, more females than males in all age groups, with the exception of 30--39 years, reported OAUs of longer duration. We found no significant differences between males and females in all age groups, with the exception of 30--39 years (*t*(60) = 2.520, *P* = 0.014). A similar trend was observed in the control group, with more females than males in all age groups, with the exception of 20--29 years, reporting OAUs of longer duration. We found significant differences in OAU duration between males and females in the 20--29-year-old and 40--49-year-old groups (*t*(107) = 2.078, *P* = 0.040 and *t*(198) = −2.554, *P* = 0.012, resp.).

3.3. Effect of OAUs on OHQOL {#sec3.3}
----------------------------

The 1-year period prevalence of BD had a negative effect on the GOHAI scores of both males and females (both *P* \< 0.001). The age-stratified analysis of mean GOHAI scores indicated that the trend observed in females with BD was similar to that in females in the control group. Males without BD had decreased GOHAI scores with age, but those in the 20--39-year-old and 70--79-year-old subgroups of BD patients had lower scores.

After adjusting for age and sex, BD patients with OAUs (where "with OAUs" was defined as ≥2 outbreaks in the last year) were more likely to have GOHAI scores below the norm. Detailed multivariate analysis results before and after stratification for sex and age are reported in [Table 3](#tab3){ref-type="table"}. Stratified analyses by sex and age suggested that the adjusted odds for GOHAI scores below the norm were highest for female BD patients with OAUs who were 60--79 years, followed by female BD patients with OAUs who were 20--39 years. The adjusted odds among control participants with OAUs were higher than were those among BD patients without OAUs.

4. Discussion {#sec4}
=============

In the present study, we confirmed that BD patients had a considerably higher frequency of OAUs and a lower OHQOL than the general population. Our sex-stratified analysis further revealed that OHQOL was particularly compromised among females with OAUs. This work corroborates the findings of a prior study indicating that BD patients had lower OHQOL than did healthy controls \[[@B9]\]. The strengths of our study were (1) the inclusion of more BD patients compared with previous studies, (2) the relatively high response rate for a mail-in survey, and (3) the inclusion of a control group drawn from the general population.

The reported 1-year period prevalence rates for RAS vary widely (5--60%), depending on the population examined, with a potential female predominance in adults \[[@B22]--[@B30]\]. According to a population study in the United States, only 1% of children had recurrent oral ulcers, but 35--40% may have had a history of RAS-like diseases, with ulceration beginning before 5 years of age \[[@B31]\]. Moreover, the prevalence of affected patients increased with age. However, a study of elderly dental patients in Thailand found RAS in only 0.7% of persons older than 70 years of age \[[@B14]\]. Because OAU status was self-reported in our study, we could not determine whether RAS was one form of BD symptoms. Nevertheless, it was clear that BD patients had a greater burden of suffering related to OAUs than did the general population.

Oral diseases give rise to significant morbidity, resulting in physical, social, and psychological consequences that affect QOL \[[@B9]\]. Oral health problems can result in pain and discomfort and lead to problems with eating, interpersonal relationships, appearance, and self-image. Pain is an important factor that can limit oral functions. Bernabé et al. showed that BD had a considerable impact on QOL as assessed by the generic questionnaire, the EuroQol (EQ-5D) \[[@B32]\].

Al-Omiri and colleagues recently found that patients with RAS reported higher levels of anxiety than did controls. Females (both patients and controls) had higher scores on the Hospital Anxiety and Depression Scale than did males \[[@B33]\]. Stress may trigger the mechanisms involved in the pathogenesis of recurrent OAUs, leading to pain and negative effects on daily activities, initiating a cycle in which stress leads to ulcers and ulcers lead to stress \[[@B33], [@B34]\]. Pain-related interference appears to be related to psychological rather than to physical characteristics \[[@B34]\]. Krisdapong et al. showed that the discomfort of RAS primarily affected eating and tooth brushing \[[@B35]\]. Our findings show that those in the control group who had OAUs had a lower OHQOL than did BD patients without OAUs. Indeed, recurrent OAUs may have a major negative impact on the OHQOL of not only patients but also of healthy individuals. Prevention of and treatment for OAUs may play an important role in maintaining or improving QOL, particularly in BD patients.

In our study, female BD patients with two or more OAUs within 1 year had almost double the risk for a subnormal GOHAI score than did their male counterparts. This difference should be evaluated further given that it persisted after multivariate adjustment. Gur et al. suggested that BD patients could benefit from psychoeducational or self-management interventions aimed at enhancing self-esteem and ability to manage their disease and its symptoms on a daily basis. They showed that such programs could improve patients\' physical and psychological functioning \[[@B8]\].

Although an association between HLA-B\*51 and RAS has been reported \[[@B36]\], the findings remain inconsistent \[[@B37], [@B38]\]. Oral streptococci have been suggested as important determinants of RAS, either as direct pathogens or as an antigenic stimulus culminating in the genesis of antibodies that may cross-react with keratinocyte antigenic determinants \[[@B39]--[@B41]\].*Helicobacter pylori* \[[@B42], [@B43]\], herpes viruses \[[@B44]--[@B46]\],*Varicella zoster* virus \[[@B47]\], and cytomegalovirus \[[@B47], [@B48]\] have also been implicated in RAS. Our study could not analyze the associations between these factors and OAUs because of a lack of information.

This study had several limitations. First, the cross-sectional nature of the data restricts our ability to make inferences regarding the direction of associations. However, it is less reasonable to believe that the domains of QOL affect the 1-year period prevalence OAUs than vice versa. Second, we used a mail-in questionnaire for data collection, and the diagnosis of BD was self-reported. However, we analyzed the data from only those subjects who provided a confirmed year of BD diagnosis. It is unlikely that this practice resulted in misclassifications. Third, this study focused on the frequency of OAUs but not on their severity. Finally, it has been suggested that various physiological and biochemical factors are associated with recurrent aphthous ulcers (e.g., smoking and other lifestyle habits). These factors should be evaluated in greater detail according to the different clinical presentations of the disease.

In conclusion, our data indicate that having OAUs has a negative impact on OHQOL, particularly for female BD patients. Caring for OAUs may be a critical factor in maintaining and improving the QOL of BD patients. Associations between biological features, such as HLA-B\*51, and the prevalence of OAUs remain unknown. A more detailed analysis including biological factors may reveal additional associations between OAUs and BD.
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###### 

Characteristics of study participants in the final analysis (*n* = 1,772).

  Variable             BD patients   Controls         
  -------------------- ------------- ---------- ----- --------
  Sex                                                  
   Male                349           (51.7)     532   (48.5)
   Female              326           (48.3)     565   (51.5)
  Age                                                  
   20--29              22            (3.3)      109   (9.9)
   30--39              62            (9.2)      195   (17.8)
   40--49              112           (16.6)     200   (18.2)
   50--59              183           (27.1)     231   (21.1)
   60--69              212           (31.4)     206   (18.8)
   70--79              84            (12.4)     156   (14.2)
  Disease severity                                     
   No symptoms         89            (13.2)            
   I                   283           (41.9)            
   II                  131           (19.4)            
   III                 31            (4.6)             
   IV                  91            (13.5)            
   V                   17            (2.5)             
   Unknown             33            (4.9)             
  Drug treatment                                       
   Colchicines         217           (33.8)            
   Steroids            201           (31.0)            
   Immunosuppressant   56            (8.4)             
   Other(s)            152           (23.3)            

###### 

One-year period prevalence, frequency, and mean total duration of OAUs during the past year in the general population (controls) and BD patients according to sex and age (*n* = 1,772).

  Sex, age   No. BD patients^a^/no. controls^a^   BD patients   Controls   *P*-value                                                                                                                
  ---------- ------------------------------------ ------------- ---------- ------------ ---------- ------------ ---------- --------- ----------- --------- ------------ ------------- ------------- -------------
  Males                                                                                                                                                                                              
   20--29    11/64                                81.8          24.4       (30.9)       38.3       (38.6)       54.7       2.8       (4.0)       13.1      (21.7)       0.091         0.043         0.059
   30--39    25/93                                100.0         32.0       (52.5)       111.0      (104.7)      38.7       1.3       (2.2)       6.5       (14.2)       \<0.001       0.007         \<0.001
   40--49    61/90                                90.2          16.1       (47.3)       60.5       (91.0)       25.6       1.1       (2.9)       3.0       (8.5)        \<0.001       0.016         \<0.001
   50--59    102/111                              80.4          9.0        (11.8)       47.4       (68.9)       23.4       0.6       (1.6)       2.3       (5.6)        \<0.001       \<0.001       \<0.001
   60--69    109/110                              67.0          10.2       (35.8)       39.7       (68.1)       16.4       0.6       (2.5)       1.6       (4.8)        \<0.001       0.006         \<0.001
   70--79    41/64                                73.2          6.2        (10.4)       34.6       (66.3)       15.6       0.3       (0.9)       1.5       (5.9)        \<0.001       0.001         0.003
   Total     **349/532**                          **78.5**      **12.4**   **(33.1)**   **61.7**   **(77.2)**   **27.8**   **1.0**   **(2.6)**   **4.2**   **(11.5)**   **\<0.001**   **\<0.001**   **\<0.001**
  Females                                                                                                                                                                                            
   20--29    11/45                                100.0         9.6        (9.5)        47.3       (34.2)       51.1       1.7       (2.7)       6.8       (9.5)        0.003         0.021         0.003
   30--39    37/102                               94.6          9.3        (10.5)       57.2       (63.3)       49.0       1.7       (2.5)       7.6       (14.2)       \<0.001       \<0.001       \<0.001
   40--49    51/110                               94.1          18.9       (52.5)       89.2       (88.8)       41.8       1.5       (2.6)       7.4       (15.6)       \<0.001       0.022         \<0.001
   50--59    81/120                               91.4          14.4       (26.5)       65.7       (79.8)       30.8       1.0       (2.4)       4.1       (10.9)       \<0.001       \<0.001       \<0.001
   60--69    103/96                               83.5          8.5        (10.8)       50.0       (75.2)       13.5       0.4       (1.1)       1.5       (5.4)        \<0.001       \<0.001       \<0.001
   70--79    43/92                                88.4          18.2       (40.7)       57.4       (75.6)       25.0       0.7       (1.8)       4.3       (15.0)       \<0.001       0.007         \<0.001
   Total     **326/565**                          **89.6**      **13.0**   **(29.6)**   **61.7**   **(77.2)**   **34.0**   **1.1**   **(2.3)**   **5.2**   **(12.7)**   **\<0.001**   **\<0.001**   **\<0.001**

^a^All BD patients and controls were analyzed, regardless of the 1-year period prevalence of OAUs.

###### 

Odds ratios (with 95% CI) for GOHAI scores lower than Japanese norms based on 1-year period prevalence of OAUs^a^ in the past year for controls and BD patients.

  Group^a^           Total     Males             Females                                                                                      
  ------------------ --------- ----------------- ----------------- --------- ----------------- ----------------- --------- ------------------ ------------------
  All ages                                                                                                                                     
   GP without OAUs   523/319   1                 1                 268/153   1                 1                 255/166   1                  1
   GP with OAUs      107/148   2.3 (1.7--3.0)    2.6 (2.0--3.5)    47/64     2.4 (1.6--3.7)    2.8 (1.8--4.3)    60/84     2.2 (1.5--3.2)     2.6 (1.8--3.9)
   BD without OAUs   87/59     1.1 (0.8--1.6)    1.0 (0.7--1.4)    60/38     1.1 (0.7--1.7)    0.9 (0.6--1.4)    27/21     1.2 (0.7--2.2)     1.0 (0.6--1.8)
   BD with OAUs      113/416   6.0 (4.7--7.8)    6.2 (4.8--8.0)    73/178    4.3 (3.0--6.0)    4.4 (3.1--6.1)    40/238    9.1 (6.2--13.5)    9.3 (6.4--13.6)
  20--39 years                                                                                                                                 
   GP without OAUs   131/55    1                 1                 69/27     1                 1                 62/28     1                  1
   GP with OAUs      65/53     1.9 (1.2--3.1)    1.9 (1.2--3.1)    33/28     2.2 (1.1--4.2)    2.2 (1.1--4.3)    32/25     1.7 (0.9--3.4)     1.7 (0.9--3.4)
   BD without OAUs   3/4       3.1 (0.7--14.7)   3.1 (0.7--14.2)   1/1       2.6 (0.2--42.3)   2.7 (0.2--44.6)   2/3       3.3 (0.5--21.0)    3.5 (0.6--22.3)
   BD with OAUs      19/58     7.3 (4.0--13.3)   7.5 (4.0--13.8)   10/24     6.1 (2.6--14.5)   6.1 (2.6--14.4)   9/34      8.4 (3.5--19.8)    9.8 (4.1--23.7)
  40--59 years                                                                                                                                 
   GP without OAUs   212/123   1                 1                 112/57    1                 1                 100/66    1                  1
   GP with OAUs      35/61     3.0 (1.9--4.8)    2.9 (1.8--4.8)    10/22     4.3 (1.9--9.7)    4.4 (1.9--9.9)    25/39     2.4 (1.3--4.3)     2.5 (1.4--4.6)
   BD without OAUs   32/21     1.1 (0.6--2.0)    1.2 (0.7--2.2)    26/13     1.0 (0.5--2.1)    0.9 (0.4--1.9)    6/8       2.0 (0.7--6.1)     1.6 (0.6--4.8)
   BD with OAUs      63/179    4.9 (3.4--7.0)    5.0 (3.4--7.1)    41/83     4.0 (2.4--6.5)    4.1 (2.5--6.7)    22/96     6.6 (3.8--11.6)    6.8 (3.9--11.9)
  60--79 years                                                                                                                                 
   GP without OAUs   180/141   1                 1                 87/69     1                 1                 93/72     1                  1
   GP with OAUs      7/34      6.2 (2.7--14.4)   6.1 (2.6--14.3)   4/14      4.4 (1.4--14.0)   4.6 (1.4--14.7)   3/20      8.6 (2.5--30.1)    8.2 (2.3--28.9)
   BD without OAUs   52/34     0.8 (0.5--1.4)    1.0 (0.6--1.6)    33/24     0.9 (0.5--1.7)    1.0 (0.5--1.8)    19/10     0.7 (0.3--1.6)     0.8 (0.4--1.8)
   BD with OAUs      31/179    7.4 (4.7--11.5)   8.3 (5.3--13.0)   22/71     4.1 (2.3--7.2)    4.9 (2.7--8.9)    9/108     15.5 (7.3--32.7)   15.2 (7.5--30.6)

^a^For purposes of analysis, the cutoff for "with OAUs" was ≥2 OAU outbreaks within the last year.

^b^Adjusted for age and sex.

^c^Adjusted for age.

[^1]: Academic Editor: Haner Direskeneli
